Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Fast and Easy Money in Penny Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Don Coulter who wrote (432)	2/16/1999 10:48:00 AM
From: Tracy Moore	Respond to of 3517

The FEMPS "Play of the Day" is PRXX at .50... I'm hearing news to be released later today... about 5 out, with less than a mil float... Their main focus is Psoriasis... a condition with no known cure... if they come out with a major "strategic relationship" today I'm seeing $2-$3 by Thursday... Praxis is a Nevada-incorporated pharmaceutical company with research and development laboratories at the John Curtin School of Medicine in Canberra, Australia. Its corporate headquarters is in Vancouver, British Columbia, Canada. Highlights: -- Research and Development costs for medical technology licensed by Praxis, incorporating world-wide patents, exceeds $7 million to date. -- Praxis medical research team is recognized internationally for its work in carbohydrate drugs and has had products licensed by multi-national drug companies. -- Current product development for psoriasis, surgical adhesions, ocular inflammation and facial wrinkles. Some 110 million people in America are affected by these conditions. Second generation product currently under development will be patented shortly for use in treatment of diabetes, arthritis and multiple sclerosis. -- Drugs under development are considered to be safer and more reliable than current treatments available. Products have outstanding pharmacological and toxicological characteristics. -- Market for products currently under development by Praxis exceeds $8 billion in the United States. -- The two doctors who are principal shareholders and management executives are internationally recognized in their respective fields of medical research. Dr. Brett Charlton has been published in more than 50 national and international medical and biomedical journals. Dr. Bill Cowden is the author of over 100 research papers published in scientific and medical journals. The John Curtin School of Medicine, where Praxis has its laboratories in Canberra, is a world-renowned medical center which has had two of its staff awarded Nobel Prizes in Medicine. -- Stage 1 and II Clinical trials to begin in September 1998. WOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO!!!!!! Its FAST and EAAAAAAAAAAAAAAAAAAAAAAAAAAAAAASY MONEEEEEEEE!!!!